HC Wainwright & Co. reiterated coverage on Kala Pharmaceuticals with a new price target
$KALA
Biotechnology: Pharmaceutical Preparations
Health Care
HC Wainwright & Co. reiterated coverage of Kala Pharmaceuticals with a rating of Buy and set a new price target of $11.00 from $14.00 previously